Welcome to our dedicated page for RGNT news (Ticker: RGNT), a resource for investors and traders seeking the latest updates and insights on RGNT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RGNT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RGNT's position in the market.
Regentis Biomaterials (NYSE American: RGNT) priced its initial public offering of 1,250,000 ordinary shares at $8.00 per share, for aggregate gross proceeds of $10,000,000, with a 45-day underwriter option to purchase up to an additional 187,500 shares. The Ordinary Shares are expected to begin trading on December 4, 2025, and the Offering is expected to close on or about December 5, 2025, subject to customary closing conditions.
The company intends to use net proceeds primarily for development activities, including completing its pivotal trial and preparing the PMA submission for GerlinC, and for corporate purposes including repayment of certain debt and deferred compensation. ThinkEquity is sole book-running manager.
